To evaluate the efficacy and safety of tebentafusp in patients with metastatic uveal melanoma from the establishment of the databases to October 13, 2025.
Key Findings:
A total of six studies involving 850 participants were included, with 631 patients receiving tebentafusp.
Median overall survival (OS) was 21.3 months and median progression-free survival (PFS) was 3.6 months.
Response rates included partial response (PR) at 9% (95% CI: 5% to 14%), stable disease (SD) at 39% (95% CI: 35% to 43%), and progressive disease (PD) at 79% (95% CI: 32% to 97%).
Cytokine release syndrome (CRS) occurred in 88% of patients, with 2% experiencing grade ≥ 3 CRS.
Treatment-related adverse events (trAEs) occurred in 98% of patients, with 41% experiencing grade ≥ 3 trAEs.
Interpretation:
Tebentafusp shows modest survival benefits in metastatic uveal melanoma patients despite low response rates, with manageable adverse events that warrant consideration.
Limitations:
The study suggests the need for further multi-center randomized controlled trials to enhance the robustness of findings.
Sample size limitations may affect the robustness of the findings, necessitating larger studies.
Conclusion:
Tebentafusp exhibits modest but potentially meaningful survival benefit despite low response rates for metastatic uveal melanoma patients, highlighting the need for further research.
